- ASSISTANT PROFESSOR Genetics and Genomic Sciences
2010 - 2011
The 2010 world congress in computer science, computer engineering and Applied computing
2005 - 2007
SIEMENS AG. Germany
Dr. Rui Chang’s Lab
Computational Biology, Systems Biology, Network Biology, Gene Expression/Phenotype Prediction, Regulatory Network and Signaling Pathway Reconstruction, Bayesian Networks,
The researches in Dr. Chang’s lab broadly cover the topics within the field of Systems Biology. In particular, we are focused on dissecting the gene regulatory networks and signaling pathways in human diseases, such as cancer and human developments, such as human embryonic, adult stem cells, by developing and integrating cutting-edge reverse engineering approaches and statistical models. Secondly, we are interested in reconstructing genome-wide and context-specific predictive network models of human cells to interrogate impact of underpinning biological process to the development of both physiological and pathological phenotypes and generate in-silico hypothesis in combination with laboratory validations towards next generation genetic therapy.
Dr. Chang’s lab is interested in a variety of interdisciplinary themes covering machine learning, graphical models, Bayesian networks and the biological sciences, including:
1) Novel method development: Developing novel reverse-engineering approaches and statistical models to reconstructing signaling pathways and predictive network model of human diseases which encompassing multi-scale molecule interactions, such as transcriptional regulations and protein-protein interactions. Based on the predictive model, to generate in-silico hypothesis and identify drug targets towards next generation genetic therapy.
2) Human disease modeling: Integrating multi-scale -omics data in cancer and other human pathology by leveraging the cutting-edge network modeling approaches to dissect genome-wide and disease-specific molecular interaction network and identify dysregulated signaling pathways towards prediction and validate of novel drug targets. Current projects are extensively focusing on modeling various types of human cancer.
3) Human development and regenerative medicine: Dissecting the genetic regulatory network in human embryonic stem cells, adult stem cells and cancer stem cells for stem cell pluripotency, self-renewal. Predict and validate high-efficiency and high-safety recipes for disease-specific stem cell reprogramming and lineage-specific differentiation towards cell replacement therapy.
Two postdoc positions are currently available in Dr. Rui Chang’s lab:
Prospective candidates should have a recent PhD degree in computer science, mathematics, bioinformatics/computational biology discipline and high motivation to pursue independent research in computational biology. Applicants are expected to have a solid background in programming and computational techniques, with a working knowledge of molecular biology and genetics being highly desirable.
Position 1: Applicants who desired to focus on method developments and software development:
Prospective candidates should have a recent PhD degree in computer science specialized in machine learning, mathematics, statistics or physics. Strong working experiences in Bayesian networks and other graphical models is highly preferred. Candidate must have strong programming skills in C/C++/Java, Matlab and R. Programming skills in other language is a plus. Basic knowledge in biology and hands-on experience in computational biology is highly desired but not required. The candidate will be responsible for developing cutting-edge machine learning approaches based on graphical models and other mathematical models, and is expected to develop software platforms towards real-world human disease network modeling and drug target prediction by working closely with disease modeling team.
Position 2: Applicants who desired to focus on real-world disease modeling:
Prospective candidates should have a recent PhD degree in computer science, bioinformatics (computational biology) or biology science. Candidate must have strong knowledge in biology, genomics, and hands-on experience in computational biology projects involves analyzing and integrating omics data. Candidate should have a good programming skills in C/Java, Matlab or R. Programming skills in other language is a plus. Basic knowledge about graphical models, machine learning approaches is required. Strong understanding on Bayesian network is highly desired, but not required. The candidate will be responsible for integrating and analyzing multi-scale omics data and leverage cutting-edge method to reconstruct disease network and drug targets validation by working closely with method development team and laboratory collaborators.
Exceptional candidate have both strong machine learning background and biology knowledge can be considered to work cross projects and fields.
Please send CV and three reference letters to email@example.com
Schadt E, Chang R. A Global Positioning System for Navigating DNA to Enhance the Construction of Disease Associated Regulatory Networks. Science 2012;.
Chang R, Shoemaker R, Wang W. Systematic Search for recipes to generate induced Pluripotency Stem Cells. PLoS Computational Biology 2011 Dec; 7(12).
Chang R, Shoemaker R, Wang W. A novel knowledge-driven systems biology approach for phenotype prediction upon genetic intervention. IEEE/ACM transactions on computational biology and bioinformatics / IEEE, ACM 2011; 8(5).
Chang R, Brauer W, Stetter M. Modeling semantics of inconsistent qualitative knowledge for quantitative Bayesian network inference. Neural networks : the official journal of the International Neural Network Society 2008; 21(2-3).
Chang R, Stetter M, Brauer W. Quantitative Inference by Qualitative Semantic Knowledge Mining with Bayesian Model Averaging. IEEE Transactions on Knowledge and Data Engineering 2008; 20(12).
Chang R, Wang W. Novel algorithm for Bayesian network parameter learning with informative prior constraints. IEEE Transactions on Knowledge and Data Engineering 2010 October; 18(23).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Chang did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 3 Room 3L-31
1425 Madison Avenue
New York, NY 10029